Bioton insulin producer buys a stake of HTL-Strefa

APA - Austria Presse Agentur
03-11-2006, 11:56

Warsaw (Puls Biznesu) – Bioton, the listed insulin producer, will be a substantial shareholder of HTL-Strefa which is going to be listed soon. The transaction would bring synergies to both companies.

Warsaw (Puls Biznesu) – Bioton, the listed insulin producer, will be a substantial shareholder of HTL-Strefa which is going to be listed soon. The transaction would bring synergies to both companies.

 

Biotons is going to become the shareholder of HTL-Strefa with over 5 percent share in the capital and votes, “PB” has learnt unofficially. The reduction in the book building of the producer of medical equipment which exceeded 97 percent was caused by the insulin producer. “PB” did not manage to get comments from Adam Wilczega, Bioton CEO, who is abroad. Andrzej Czernecki, the head of HTL-Strefa, did not want to comment. He admitted, however that there is big potential in cooperation of the two firms.

“We could deliver our products to Bioton to fill its offer. Bioton on the other hand has big sales markets, especially in Asia, which is very interesting to us”, Andrzej Czernecki said.

 

After HTL-Strefa issue prospectus was approved of, there were rumors that Bioton could take part in the IPO. Bioton’s management admitted the company could consider buying a stake. Both companies talked about direct cooperation before. In the recent book building HTL-Strefa divided its shares among 60 institutional investors. Subscription ends on Monday. HTL-Strefa wants to be listed on November 15th.

© ℗
Rozpowszechnianie niniejszego artykułu możliwe jest tylko i wyłącznie zgodnie z postanowieniami „Regulaminu korzystania z artykułów prasowych” i po wcześniejszym uiszczeniu należności, zgodnie z cennikiem.

Podpis: APA - Austria Presse Agentur

Najważniejsze dzisiaj

Polecane

Inspiracje Pulsu Biznesu

Puls Biznesu

Inne / Bioton insulin producer buys a stake of HTL-Strefa